



The Role of Lactate Isomers in Cancer

Guest Editors:

Dr. Lidia de Bari

Institute of Biomembranes,
Bioenergetics and Molecular
Biotechnologies (IBIOM), Italian
National Research Council (CNR),
Bari, Italy

Dr. Miklós Péter Kalapos

Theoretical Biology Research
Group, Budapest, Hungary

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear colleagues,

L- and D-lactate both derive from the triose phosphate intermediates of glycolysis. Since the rate of glycolysis increases in tumors, both L- and D-lactate formation could be considered a hallmark of increased glucose consumption in cancer. Even if far less is known about D-lactate than L-isomer, especially in cancer, the importance of both L- and D-lactate formation, transport, and metabolic fate clearly emerges from earlier and recent discoveries.

This Special Issue focuses on the study of lactate isomers, from their production to their transport and oxidation, both in normal and cancer cells, stressing the role of these compounds in cell metabolism, signaling, as well as in cell interactions within the tumor. Studies exploring the involvement of mitochondria in these processes are also welcome.

We firmly believe that the present Special Issue, by bringing together all the achievements on lactate biochemistry, will represent an important overview on this complex topic and highlight the missing tiles from a mosaic that promises to indicate novel therapeutic perspectives for the cure of cancer patients.

We look forward to receiving your contributions.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI